Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: MESO 2 – 4 TWST Matrix Metrics: MESO 3 – 5 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin).

  • Growth vs. Quality Trade-Off: TWST earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. MESO 34.6/100 SELL) and 3.15β · 127% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs TWST
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.85
-5.15% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.15β · 127% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.9 · SMA20: $137.33 · SMA50: $149.84

6-Pillar Scorecard Institutional Category Breakdown (MESO 2 – 4 TWST)

Columns: Metric · MESO · TWST
1. Valuation Multiples MESO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 14.1x 17.5x
2. Growth & Scale TWST
Revenue Growth (YoY) +390.7% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M $432M
Market Cap $1.7B $7.6B
3. Profitability & Quality TWST
Gross Margin 80.0% 52.0%
Operating Margin -42.6% -31.9%
Net Profit Margin -47.8% -31.7%
Return on Equity (ROE) -9.9% -29.6%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$115M EBITDA
Cash Flow Margin -37.1% EBITDA Mgn -26.7% EBITDA Mgn
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $7.11 Book/Sh · -29.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 76.8% (37th %ile) 93.2% (18th %ile)
Put/Call OI Skew Thin ADR Chain 1.04x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 83.9% of Rev ($362M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (3) vs TWST (5)
Institutional Metric MESO TWST Criterion Row Edge
Market Capitalization
Scale
$1.7B $7.6B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+390.7% +23.2% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -31.9% Higher Margin TWST
Net Profit Margin
Profitability
-47.8% -31.7% Higher Margin TWST
Return on Equity (ROE)
Capital Efficiency
-9.9% -29.6% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 42% ($23–$220) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 3.15β · 127% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 51.7 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$120M $432M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% 52.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · 17.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +14.16 pp
MESO: -6.1% · TWST: -20.26%
3M Horizon TWST +16.36 pp
MESO: -25.19% · TWST: -8.83%
6M Horizon TWST +127.41 pp
MESO: -14.82% · TWST: +112.59%
1Y Horizon TWST +270.43 pp
MESO: -16.42% · TWST: +254.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs TWST. Trailing 12-month operating profitability (MESO -42.6% vs TWST -31.9%) and valuation multiples (MESO N/M vs TWST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
TWST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$432M
Gross Margin52.0%
Op. Margin-31.9%
ROE / Fwd P/E-29.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ MESO vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin). Growth vs. Quality Trade-Off: TWST earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. MESO 34.6/100 SELL) and 3.15β · 127% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $432M for TWST. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.

MESO screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus TWST (-29.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.15β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.